Earnings summaries and quarterly performance for Foghorn Therapeutics.
Executive leadership at Foghorn Therapeutics.
AG
Adrian Gottschalk
Detailed
Chief Executive Officer
CEO
AQ
Alfonso Quintás-Cardama
Detailed
Chief Medical Officer
AR
Anna Rivkin
Detailed
Chief Business Officer
CC
Carlos Costa
Detailed
Chief People Officer
KH
Kristian Humer
Detailed
Chief Financial Officer
ML
Michael LaCascia
Detailed
Chief Legal Officer
SB
Steven Bellon
Detailed
Chief Scientific Officer
Board of directors at Foghorn Therapeutics.
Research analysts covering Foghorn Therapeutics.
Recent press releases and 8-K filings for FHTX.
Foghorn Therapeutics Discusses Pipeline Progress and Recent Financing at TD Cowen Conference
FHTX
New Projects/Investments
Guidance Update
- Foghorn Therapeutics (FHTX) is a clinical-stage biotech company focused on oncology, with both partnered and proprietary pipelines.
- The FHD-909 program, partnered 50/50 with Eli Lilly, is in Phase 1 dose escalation for SMARCA2, with a decision on moving to dose expansion anticipated around mid-2026. The company has not yet reached the maximum tolerated dose but is backfilling cohorts.
- Foghorn's proprietary pipeline includes selective CBP and EP300 degrader programs, with IND-enabling studies on track for later in 2026, and an ARID1B degrader program targeting in vivo proof of concept in 2026.
- The company recently completed a $50 million registered direct offering in January 2026, which provides approximately two quarters of spend at its current burn rate.
4 days ago
Foghorn Therapeutics Discusses Clinical Progress and Recent Financing
FHTX
New Projects/Investments
Guidance Update
- Foghorn Therapeutics' FHD-909 program, partnered 50/50 with Eli Lilly, is currently undergoing dose escalation with backfilling for non-small cell lung cancer patients, and a decision on moving to dose expansion is anticipated around mid-2026, plus or minus a few months. The molecule has demonstrated good safety and tolerability to date.
- The company is advancing its proprietary protein degrader pipeline, with IND-enabling studies planned later in 2026 for selective CBP (FHT-171) and EP300 programs, and in vivo proof of concept targeted for 2026 for the ARID1B degrader.
- Foghorn Therapeutics completed a $50 million registered direct offering in January 2026, which was priced at a 30% premium to its trading price and provides approximately two quarters of spend at the current burn rate.
4 days ago
Foghorn Therapeutics Provides Clinical Pipeline Update and Recent Financing Details
FHTX
New Projects/Investments
Guidance Update
- Foghorn Therapeutics is a clinical-stage biotech company focused on oncology, with a pipeline that includes a partnered program with Eli Lilly and proprietary programs.
- The FHD-909 (SMARCA2) program, partnered 50/50 with Eli Lilly, is currently in dose escalation with backfilling of cohorts, and a decision on moving to dose expansion is anticipated around mid-2026.
- The company's proprietary pipeline includes selective CBP and EP300 programs, for which IND-enabling studies are expected later in 2026, and an ARID1B degrader program aiming for in vivo proof of concept in 2026.
- Foghorn completed a $50 million registered direct offering in January, priced at a 30% premium, which provides approximately two quarters of spend coverage at the current burn rate.
4 days ago
Foghorn Therapeutics Provides Update on SMARCA2 Program and Wholly-Owned Pipeline
FHTX
New Projects/Investments
Guidance Update
- Foghorn Therapeutics' most advanced program, SMARCA2, in collaboration with Eli Lilly, commenced dosing patients in a Phase 1 study in October 2024 for non-small cell lung cancer (NSCLC) patients with SMARCA4 mutations.
- The collaboration anticipates having sufficient information by mid-2026 to decide on advancing the SMARCA2 program into the dose expansion phase.
- CEO Adrian Gottschalk expects to see single-agent activity from the SMARCA2 inhibitor, emphasizing the significant unmet need in SMARCA4-mutated NSCLC patients.
- The company is also progressing wholly-owned programs, including CBP for ER-positive breast cancer, which recently completed non-GLP tox studies, and EP300 for hematological malignancies, tracking for non-GLP tox studies by mid-2026.
Feb 11, 2026, 8:00 PM
Foghorn Therapeutics Provides Update on SMARCA2, CBP, and EP300 Programs
FHTX
New Projects/Investments
Guidance Update
- Foghorn Therapeutics' most advanced program, SMARCA2, in collaboration with Eli Lilly, began dosing patients in its Phase 1 study in October 2024. A decision on moving to dose expansion is expected around mid-2026.
- The SMARCA2 program targets non-small cell lung cancer patients with SMARCA4 loss-of-function mutations, representing an estimated 15,000 patients annually in the U.S..
- For its wholly-owned programs, the CBP program recently completed non-GLP tox studies, with further in vivo work and IND preparation underway for a potential Phase 1 study in ER-positive breast cancer.
- The EP300 program is on track to begin non-GLP tox studies by mid-2026, targeting hematological malignancies.
Feb 11, 2026, 8:00 PM
Foghorn Therapeutics Provides Update on Oncology Pipeline Development
FHTX
New Projects/Investments
Product Launch
- The SMARCA2 program, partnered with Eli Lilly, began patient dosing in its Phase 1 study in October 2024. The collaboration anticipates having enough information by mid-2026 to decide on advancing to the dose expansion phase.
- Foghorn's wholly-owned CBP program, targeting ER-positive breast cancer, recently completed non-GLP toxicology studies with all animals surviving and is moving towards an Investigational New Drug (IND) application.
- The EP300 program, focused on hematological malignancies, is projected to start non-GLP toxicology studies by mid-2026.
- The company estimates the annual addressable market for its SMARCA2 inhibitor in non-small cell lung cancer to be approximately 15,000 patients in the U.S..
Feb 11, 2026, 8:00 PM
Foghorn Therapeutics' FHD-286 Drug Response Predicted by Yatiri Bio's Platform
FHTX
New Projects/Investments
- Yatiri Bio's ProteoCharts™ platform demonstrated 100% concordance in predicting clinical outcomes for Foghorn Therapeutics' FHD-286 in a blinded retrospective study involving patients with relapsed or refractory acute myeloid leukemia (R/R AML) or myelodysplastic syndrome (MDS).
- The platform accurately identified patients who achieved complete or partial responses (CR/PR) and those who experienced stable disease or treatment failure, using only pre-dose peripheral blood samples.
- Following this validation, Yatiri Bio and Foghorn Therapeutics signed a collaboration agreement for Foghorn to supply material for the further clinical development of FHD-286, with clinical and sales milestones valued at >$40M.
Feb 10, 2026, 11:00 AM
Foghorn Therapeutics Closes $50 Million Registered Direct Financing
FHTX
- Foghorn Therapeutics Inc. announced the closing of a $50 million registered direct financing on January 13, 2026.
- The financing included the sale of 2,030,314 shares of common stock at $6.71 per share, which represented a 30% premium over the Nasdaq Global Market price on January 9, 2026.
- The offering also involved pre-funded warrants to purchase up to 5,421,250 shares at $6.7099 each and series warrants for up to 3,725,782 shares at $13.42 per share and another 3,725,782 shares at $20.13 per share.
- Key participants in the financing included existing shareholders BVF Partners, Deerfield Management, and Flagship Pioneering, along with a leading biotech mutual fund.
Jan 13, 2026, 9:05 PM
Foghorn Therapeutics Secures $50 Million Equity Financing and Updates Pipeline Progress
FHTX
New Projects/Investments
Convertible Preferred Issuance
- Foghorn Therapeutics Inc. raised approximately $50.0 million in an equity financing, which is anticipated to close on January 13, 2026.
- The financing involved the sale of 2,030,314 shares of common stock at $6.71 per share, pre-funded warrants for 5,421,250 shares, and additional Series 1 and Series 2 warrants for 7,451,564 shares. The offering price for common stock represented a 30% premium to the closing stock price on January 9, 2026.
- This transaction is expected to result in a strong balance sheet with an estimated $208.9 million in cash, cash equivalents, and marketable securities as of January 13, 2026, extending the cash runway into the first half of 2028.
- The company provided updates on its pipeline, including the Phase 1 dose-escalation trial of FHD-909 advancing as planned, the Selective CBP degrader program on track to be IND-ready in 2026, and the Selective EP300 degrader program tracking to IND-enabling studies in 2026.
Jan 12, 2026, 1:50 PM
Foghorn Therapeutics Updates on Lilly Partnership and Pipeline Progress
FHTX
New Projects/Investments
Guidance Update
- Foghorn Therapeutics (FHTX) is a clinical-stage oncology company leveraging a drug discovery engine focused on chromatin biology to target historically undruggable proteins.
- Its primary program, the SMARCA2 inhibitor FHD-909, is part of a partnership with Eli Lilly, which included $300 million in upfront cash and $80 million in equity. This collaboration involves 50/50 cost-sharing and economics in the U.S. for the SMARCA2 program.
- Lilly is anticipated to make a decision on advancing FHD-909 into a dose expansion study in H1 2026. The company aims for a 15%+ response rate and 3+ months duration of therapy in the 3rd/4th line setting for SMARCA4 mutant cancers to consider it a success for expansion.
- Foghorn reported a cash position of $180 million at the end of Q3, which is projected to fund operations into early 2028, covering current program advancements.
Nov 19, 2025, 10:30 AM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more